Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
Medically reviewed by Drugs.com.
By Carole Tanzer Miller HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows.
The test of tirzepatide, brand named Zepbound, included 731 patients with diastolic heart failure and obesity who were followed for two years.
"This class of drugs continue to show benefits far beyond weight loss," said researcher Dr. Christopher Kramer, chief of cardiovascular medicine at UVA Health. "This drug will become an important part of the armamentarium for patients with obesity-related heart failure and preserved heart function."
In nearly half of heart failure cases, the left ventricle of the heart becomes stiff and can no longer pump blood properly. Doctors call this diastolic heart failure or heart failure with preserved ejection fraction.
Obesity is a major cause of heart failure, so Kramer's team wondered if the weight-loss drug tirzepatide could help.
The new trial -- published in four journals and reported Saturday at an American Heart Association meeting in Chicago -- showed that tirzepatide offered big benefits for managing heart failure.
Patients saw improvements in how far they could walk in six minutes and big decreases in a biological marker used to measure inflammation and predict risk of serious heart events, the study found.
During the two-year follow-up, 56 participants who received a placebo died or saw their heart failure get worse, compared to 36 who took tirzepatide.
Those who took tirzepatide also slimmed down, losing 11.6% of their body weight, on average.
Side effects were mostly mild -- nausea and diarrhea, researchers said.
Kramer also led a companion study that examined how the drug affected the structure and function of participants' hearts. MRIs showed beneficial reductions in the heart's weight and surrounding fat.
"This drug is reversing the abnormal properties of the heart brought on by obesity," Kramer said in a UVA news release. "There is much more to those drugs than weight loss alone."
The findings appear in four journals: The New England Journal of Medicine, Nature Medicine, Circulation and the Journal of the American College of Cardiology.
Eli Lilly, maker of Zepbound, sponsored the trial.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-22 00:00
Read more
- Teens, Booze and E-Scooters: A Rising Threat as Injuries Crowd ERs
- Everything You Need to Know About Shingles & the Shingles Vaccine
- Risk for Head and Neck Cancer Lower for Coffee and Tea Drinkers
- Community-Level Social, Environmental Factors Tied to Mild Cognitive Impairment
- Pressure Ulcers During Spinal Cord Injury Hospitalization Tied to Poor Long-Term Outcomes
- Opioid Abuse Can Change the Brain
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions